ArticleJournal of veterinary science2026
Basic fibroblast growth factor preserves rabbit adipose-derived mesenchymal stromal cells in serum-free culture.
Article in Journal of veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
importanceFetal bovine serum (FBS) is widely used for mesenchymal stromal cell (MSC) expansion but carries risks of contamination, batch variability, and xenogeneic exposure that can compromise reproducibility and downstream therapeutic use.
objectiveTo develop and evaluate a rabbit adipose-derived mesenchymal stromal cell (Rab-ADMSC) serum-free medium (SFM) supplemented with growth factors that maintains key MSC characteristics.
methodsRab-ADMSCs were isolated from 3 male New Zealand White rabbits. Basic fibroblast growth factor (bFGF), transforming growth factor-β1, and insulin-like growth factor-1 were screened for support of cell viability in SFM. Cells were then cultured in α-Minimum Essential Medium with 10% FBS or in SFM supplemented with bFGF and assessed for morphology, proliferation, expression of stemness- and senescence-associated transcripts, surface marker expression, and tri-lineage differentiation potential.
resultsSFM supplemented with bFGF preserved fibroblast-like morphology and supported Rab-ADMSC expansion. Transcript levels of stemness-associated markers and senescence-associated markers were comparable between culture conditions. Rab-ADMSCs retained osteogenic, adipogenic, and chondrogenic differentiation potential. Flow cytometry showed higher expression of CD81, CD49f, and CD29 in the SFM plus bFGF condition, whereas CD34 and CD45 remained low in both conditions. CONCLUSIONS AND RELEVANCE: A tailored SFM supplemented with bFGF supports Rab-ADMSC growth while maintaining core MSC phenotypic and functional characteristics, supporting its potential use for more standardized MSC manufacturing in veterinary regenerative applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.